Nov 19-20, 2026 · Virtual Event
Scientific Programme
Two days of cross-disciplinary sessions on cardiovascular, kidney and metabolic outcomes with internationally recognised experts.
Thursday, 19 November 2026
All times are in Central European Time (CET)
Session I
Welcome and Introduction
Chair: Oliver Schnell (Munich, Germany)
Session II
Emerging Frontiers in Cardiovascular, Kidney, and Metabolic Care
Chairs: Francesco Giorgino (Bari, Italy), Alice Kong Pik Shan (Shatin, N.T., Hong Kong)
From comorbidities to a single syndrome: A new understanding of cardiovascular, renal and metabolic diseases
Neha Pagidipati (Durham, NC, USA)
Gut Hormone Agonists 2026: Emerging Therapies and New Metabolic Opportunities
Timo Mueller (Munich, Germany)
Advancing Cardiorenal Protection Through Aldosterone Synthase Inhibition
Erika Jones (Cape Town, South Africa)
Discussion
Session III
New Guidelines 2026 – Transforming Clinical Care in Chronic Diseases
Chairs: Shelley Zieroth (Winnipeg, Canada), Pardeep Jhund (Glasgow, UK)
Beyond Weight Loss: A New Framework for Pharmacological Obesity Management
Andreea Ciudin (Barcelona, Spain)
Breaking Down Silos: Translating the 2026 ESC CVD and CKD Guidelines into Integrated Cardiorenal Care
Per-Henrik Groop (Helsinki, Finland)
The 2026 ESC Heart Failure Guidelines: Key Updates for Clinical Practice
Theresa McDonagh (London, UK)
Discussion
Break
Session IV
Policy Session: Transforming Cardiometabolic Health: Advancing Science, Integrated Care and Policy
Chair: Oliver Schnell (Munich, Germany)
Welcome and Set the Scene
Oliver Schnell (Munich, Germany)
Obesity as a Cardiovascular Health Priority
Matthias Blüher; Leipzig University (Leipzig, Germany)
EU Safe Hearts Plan
Marianne Takki; European Commission (Brussels, Belgium)
From Risk Detection to Structured Care – “Modernizing Check-Up 35”
Florian Kahles; University Hospital RWTH Aachen (Aachen, Germany)
Panel Discussion: From Screening to Structured Care – Building an Interconnected Cardiometabolic Prevention Strategy
Faculty and further Participants: Winfried Klausnitzer; Heart Failure Germany (Nuremberg, Germany), Sonja Mayer; Bavarian Chamber of Pharmacists (Gröbenzell, Germany), Raffaele Napoli; University of Naples Federico II (Naples, Italy), Bart Torbeyns; European Diabetes Forum (Brussels, Belgium)
Closing Remarks
Oliver Schnell (Munich, Germany)
Session V
Satellite Symposium supported by Eli Lilly and Company – CVOTs in type 2 diabetes and obesity: past, present and future
Chair: Jonathan Rachman (UK)
Welcome and introduction
Jonathan Rachman (UK)
CVOTs in type 2 diabetes and obesity: past, present and future
John Wilding (UK)
Closing
Jonathan Rachman (UK)
Session VI
Oral Presentations – Part 1
Chair: Pinar Topsever (Istanbul, Turkey)
Oral Presentation
OP 1: Beyond cardiovascular-kidney-metabolic syndrome: towards a comprehensive nexus of cardiometabolic multiple long-term conditions
Stephan Jacob (Villingen, Germany), Andrew J. Krentz (London, UK), Peter Libby (Boston, USA), Robert Eckel (Aurora, USA)
View in Virtual Library
Oral Presentation
OP 2: What Patients With Cardiovascular-Kidney-Metabolic Syndrome Ask: A Clustering of 25 Million Patient Portal Messages
Matthias Christian Lutz (Stanford, USA)
View in Virtual Library
Oral Presentation
OP 3: Standard Cost-Utility Analyses Underestimate Value: A Multidomain Economic Model of Spotlight-AQ Digital Health in Diabetes Care
Katharine Barnard-Kelly (Southampton, UK)
View in Virtual Library
Oral Presentation
OP 4: An AI-Based Knowledge Center for Cross-Disciplinary Retrieval of Cardio-Kidney-Metabolic Clinical Guidelines
Elena Tonchevska (Munich, Germany)
View in Virtual Library
Oral Presentation
OP 5: An AI-Based Knowledge Center to Support Evidence-Based Management of Hypertension
Moritz Schroll (Munich, Germany)
View in Virtual Library
Session VII
Closing of Day 1
Chair: Oliver Schnell (Munich, Germany)
Friday, 20 November 2026
All times are in Central European Time (CET)
Session I
Type 1 Diabetes: From Disease Modification to Organ Protection
Chair: Helen M. Colhoun (Edinburgh, UK)
Rethinking Type 1 Diabetes: Screen, Detect, Prevent
Chantal Mathieu (Leuven, Belgium)
Immunomodulation in Early-Stage Type 1 Diabetes – Practical Considerations
Nikolas Hillenbrand (Frankfurt, Germany)
FINE-ONE: A New Chapter in Kidney Protection for Type 1 Diabetes?
Andreas L. Birkenfeld (Tuebingen, Germany)
Discussion
Session II
Continuous Monitoring: Current Practice and Emerging Perspectives
Chair: Antonio Ceriello (Milan, Italy)
Continuous Glucose Monitoring in Type 2 Diabetes and Basal Insulin: Implications for Cardiovascular Risk Reduction
Jochen Seufert (Freiburg, Germany)
Continuous Glucose Monitoring in Clinical Practice: Framework for Practical Implementation
Julia Mader (Graz, Austria)
Continuous Ketone Monitoring for People with Diabetes: Expert Recommendations on the Application of a New Technology
Ketan Dhatariya (Norwich, UK)
Discussion
Break
Session III
Satellite Symposium Supported by Roche Diagnostics International Ltd – Beyond HbA1c: Preserving cardio-renal function in insulin-treated type 2 diabetes through continuous glucose monitoring
Chair: Roman Vangoitsenhoven (Leuven, Belgium)
Welcome and introduction
Roman Vangoitsenhoven (Leuven, Belgium)
Dysglycaemia as an independent cardio-renal risk factor
Francesco Cosentino (Stockholm, Sweden)
Standardized CGM metrics & red flags for cardio-renal risk reduction
Roman Vangoitsenhoven (Leuven, Belgium)
Panel discussion and Q&A
Break
Session IV
Chronic Kidney Disease Treatment in Motion: From Broad Protection to Precision Care
Chairs: Beatriz Fernandez-Fernandez (Madrid, Spain), Linong Ji (Peking, China)
Changing the Trajectory of Disease Across the Cardiorenal Continuum: the Role of SGLT2 Inhibition
Christoph Wanner (Wuerzburg, Germany)
The 2026 ESC Guidelines for the Management of CVD and CKD
William Herrington (Oxford, UK)
A New Therapeutic Option for Non-Diabetic CKD? Lessons from FIND-CKD
Brandon Neuen (Sydney, Australia)
Emerging Perspectives on Focal Segmental Glomerulosclerosis – A New Era of Targeted Care for Rare Kidney Disease?
Daniel P. Gale (London, UK)
Discussion
Session V
Heart Failure Therapy in Transition: New Evidence, New Guidelines, New Treatment Strategies
Chairs: Naoki Sato (Kawaguchi, Japan), Per-Henrik Groop (Helsiki, Finland)
Non-steroidal MRA in HFpEF: From Evidence to Guideline-Based Practice
John McMurray (Glasgow, UK)
Emerging Therapies in Heart Failure: What’s Next in Pharmacological Care?
Katharina Marx-Schütt (Aachen, Germany)
Discussion
Break
Session VI
Rethinking Cardiovascular Risk Prevention
Chairs: Sigrun Halvorsen (Oslo, Norway), Zaneta Petrulioniene (Vilnius, Lithuania)
Hard-to-Control Hypertension: From Treatment Gaps to New Therapeutic Strategies
Michel Azizi (Paris, France)
Lipoprotein(a): From Inherited Risk to Targeted Prevention
Cristina Gavina (Porto, Portugal)
From Risk Factors to Risk Networks: Rethinking Cardiovascular Prevention
Eberhard Standl (Munich, Germany)
Discussion
Session VII
Multidisciplinary Strategies in Obesity, Type-2-Diabetes, and Metabolic Liver Disease
Chairs: Yehuda Handelsman (Tazana, CA, USA), Dror Dicker (Petach-Tikva, Israel)
Oral Incretins in T2D and Obesity: Evidence, Potential and Perspectives
Sean Wharton (Ontario, Canada)
Triple-Agonists: Redefining the Incretin Landscape in T2D and Obesity
Virginia Bellido (Sevilla, Spain)
The Liver in Metabolic Disease: New Perspectives on GLP-1–Based and Insulin-Sensitizing Approaches
Wendy Spearman (Cape Town, South Africa)
Metabolic Liver Health: Integrating Nutrition, Weight Management, and Complementary Hepatoprotective Strategies
Jens Marquardt (Luebeck, Germany)
Discussion
Session VIII
Primary Care for Cardiovascular Risk Prevention: Reaching Patients, Connecting Care
Chairs: Pinar Topsever (Istanbul, Turkey), Philippe Richard Domeyer (Athens, Greece)
Digital, Local, Integrated: New Models for Cardiorenal Prevention in Primary Care
Ana Cebrian (Murcia, Spain)
Reaching the Unreached: Primary Care and Risk Prevention in Rural Areas
Banshi Saboo (Ahmedabad, India)
Implementing the New ESC Heart Failure Guidelines: Practical Insights from a Heart Failure Nurse
Ekaterini Lambrinou (Limassol, Cyprus)
Discussion
Break
Session IX
Industry’s Perspective – Panel Discussion
Chair: Oliver Schnell (Munich, Germany)
Session X
Oral Presentations – Part 2
Chair: Boris Mankovsky (Kyiv, Ukraine)
Oral Presentation
OP 6: Effect of BMI on kidney–cardio outcomes with finerenone in a broad CKD population (INFINITY)
Peter Rossing (Herlev, Denmark)
View in Virtual Library
Oral Presentation
OP 7: Impact of finerenone on kidney–cardio outcomes by baseline HbA1c levels in a broad chronic kidney disease population: A pooled analysis (INFINITY)
David Cherney (Toronto, Canada)
View in Virtual Library
Oral Presentation
OP 8: Sarcopenia as a Metabolic and Inflammatory Phenotype in Patients with MASLD
Kateryna Pivtorak (Vinnytsya, Ukrain)
View in Virtual Library
Oral Presentation
OP 9: Cardiac Conditions on Death Certificate Line 1(a) Without a Cardiovascular Underlying Cause: U.S. Trends, 1999–2020
Jacob Willes (Salt Lake City, USA)
View in Virtual Library
Break
Award Session
Abstract Awards and Closing CVOT Summit 2026
Oliver Schnell (Munich, Germany)
We would like to thank the sponsors of the CVOT Summit 2026:

